Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS

All patients with amyotrophic lateral sclerosis (ALS) are treated with the same dose of riluzole: 50 mg twice daily. Reasonably large interindividual differences in clearance of the drug have been reported. The relatively small group of patients with high blood concentrations of riluzole has probabl...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the neurological sciences 2001-10, Vol.191 (1), p.121-125
Main Authors: Groeneveld, G.J, van Kan, H.J.M, Sastre Toraño, J, Veldink, J.H, Guchelaar, H.-J, Wokke, J.H.J, van den Berg, L.H
Format: Article
Language:English
Subjects:
Adult
Age Factors
Aged
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - blood
Amyotrophic Lateral Sclerosis - drug therapy
Analysis of Variance
Biological and medical sciences
CYP1A2
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Drug metabolism
Female
Genetic Variation
Humans
Linear Models
Male
Medical sciences
Middle Aged
Neurology
Neuroprotective Agents - blood
Neuroprotective Agents - pharmacokinetics
Neuroprotective Agents - therapeutic use
Polymorphism
Reproducibility of Results
Riluzole
Riluzole - blood
Riluzole - pharmacokinetics
Riluzole - therapeutic use
Smoking
Treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:All patients with amyotrophic lateral sclerosis (ALS) are treated with the same dose of riluzole: 50 mg twice daily. Reasonably large interindividual differences in clearance of the drug have been reported. The relatively small group of patients with high blood concentrations of riluzole has probably primarily influenced the efficacy and the incidence of side-effects in the previously conducted clinical trials with riluzole. Individual dosing of the drug may, in the case of large interindividual differences in serum concentrations of the drug, be necessary in the future. Exact data concerning the plasma and serum concentrations of riluzole in patients with ALS, after standardized intake of the drug, diet and blood sampling are unknown so far. In this study, inter- and intraindividual variability of serum and plasma levels of riluzole in 21 patients with “probable” or “definite” ALS were determined. The interindividual variability of peak serum levels (coefficient of variation=74%) was significantly larger than intraindividual variability ( p
ISSN:0022-510X
1878-5883
DOI:10.1016/S0022-510X(01)00613-X